COMMITTED TO IMPROVING THE HEALTH AND QUALITY OF LIFE OF CANCER PATIENTS
Our Solution
SystImmune was established in 2014 to lead the "0-to-1" innovation. Focused on oncology, we are committed to continuously innovating and developing new breakthrough cancer drugs, aiding cancer patients to gain an upper hand in the ceaseless fight against cancers.
Integrated Drug Discovery
Pre-Clinical
CMC
Clinical Development
Commercialization
Antibody Discovery
Protein Engineering
Immuno-Oncology
Process Development
Data Science
Regulatory
Clinical Operations
Clinical Development
Integrated Drug Discovery
Pre-Clinical
CMC
Clinical Development
Commercialization
AIDP
Artificial Intelligence Data Processing
Our proprietary AI-powered drug discovery & design platform
Bring the latest machine learning technologies to SI drug discovery pipelines
Integrated computational modeling and design workflows for small molecule, Peptide, and protein drug discovery
Our platform
A
Artificial
I
Intelligence
D
Development
P
Platform
HIRE ADC
Our Globally Leading Innovative ADC Platform
End-to-end capabilities enabled in-house development of the proprietary HIRE platform
ADC Drug – Massive killing of tumor cells, rapid reduction of tumor load
New toxins applied to antibodies
New antibodies applied to toxins
Our platform
H
Heterogeneity Overcoming
I
Immunogenic Death Inducing
R
Resistance Antagonizing
E
Enhanced Specificity
GNC
Our Globally Leading Drug Discovery Platform For Innovative Multi-Specific Antibodies
Well-positioned to lead the development of next-generation immuno-oncology therapies TEST
B Cell Antibody Discovery Platform
GNC Antibody Engineering Platform
High-Throughput Screening And Evaluation
Biological System Testing
CMC Platform
Our platform
G
Guidance
N
Navigation
C
Control
SEBA
Our proprietary Bi-Specific antibody platform
Designed to engage two different antigens or targets that are expressed on the surface of cells
SEBA selective binding domains separate activity from toxicity
Dual – Checkpoint
Dual – Growth factor receptor blocker
Our platform
S
Specificity
E
Enhanced
B
Bispecific
A
Antibody
Explore Pipeline
We are a group of R&D and clinical scientists and biotech professionals utilizing several advanced technology platforms to develop world class antibody-based drug therapies.
Read More
News and Publications
Connect the Future of Science.
